| 51 |
27072203 | Sunitinib-induced thrombotic microangiopathy. | 2016 Jan-Mar |
1 |
| 52 |
27103123 | Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma. | 2016 Jun |
1 |
| 53 |
27123883 | Systemic therapy for recurrent meningioma. | 2016 Aug |
2 |
| 54 |
27141054 | Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma. | 2016 Jul 1 |
4 |
| 55 |
27175586 | Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma. | 2016 Jun 21 |
2 |
| 56 |
27479949 | Recurrence of Epithelioid Hemangioendothelioma during Pregnancy: Case Report and Systematic Review. | 2016 Summer |
1 |
| 57 |
27580750 | Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism. | 2016 Sep 1 |
1 |
| 58 |
27633584 | In vitro and in vivo activities of an antitumor peptide HM-3: A special dose-efficacy relationship on an HCT‑116 xenograft model in nude mice. | 2016 Nov |
1 |
| 59 |
27718781 | Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. | 2016 Dec 8 |
1 |
| 60 |
28105174 | Improved sensitization effect of sunitinib in cancer cells of the esophagus under hypoxic microenviroment. | 2016 Dec |
1 |
| 61 |
24727344 | Claims analysis of hypertension occurrence, severity changes and patterns of antihypertensive use in cancer patients receiving vascular endothelial growth factor inhibitors. | 2015 Aug |
1 |
| 62 |
25446042 | Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives. | 2015 Jan |
1 |
| 63 |
25488966 | Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors. | 2015 May 10 |
1 |
| 64 |
25993161 | Biology and clinical management challenges in meningioma. | 2015 |
2 |
| 65 |
26015515 | Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer. | 2015 Sep 15 |
1 |
| 66 |
26108242 | TOKIO rationale and protocol: a phase II study to evaluate the activity and safety of third-line tyrosine kinase inhibitor after 2 tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma. | 2015 Nov-Dec |
1 |
| 67 |
26114873 | Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma. | 2015 |
1 |
| 68 |
26126494 | Antiangiogenic agents in gynecological cancer: State of art and perspectives of clinical research. | 2015 Oct |
4 |
| 69 |
26151457 | A phase II and pharmacodynamic study of sunitinib in relapsed/refractory oesophageal and gastro-oesophageal cancers. | 2015 Jul 14 |
1 |
| 70 |
26380584 | Decreased efficacy of drugs targeting the vascular endothelial growth factor pathway by the epigenetic silencing of FLT1 in renal cancer cells. | 2015 |
1 |
| 71 |
26386874 | Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors. | 2015 Dec |
1 |
| 72 |
26408740 | Tissue Biomarkers in Predicting Response to Sunitinib Treatment of Metastatic Renal Cell Carcinoma. | 2015 Oct |
1 |
| 73 |
26451083 | Clinical utility of ramucirumab in advanced gastric cancer. | 2015 |
2 |
| 74 |
26480622 | [THE CURRENT APPROACH TO METASTATIC RENAL CELL CARCINOMA]. | 2015 Aug |
1 |
| 75 |
26788996 | Prevention of Venous Neointimal Hyperplasia by a Multitarget Receptor Tyrosine Kinase Inhibitor. | 2015 |
1 |
| 76 |
28162293 | Treatment Of Sunitinib-Induced Hypertension In Solid Tumors By Nitric Oxid Donors. | 2015 Aug |
1 |
| 77 |
24018642 | Systematic combination screening reveals synergism between rapamycin and sunitinib against human lung cancer. | 2014 Jan 1 |
1 |
| 78 |
24025975 | Severe exacerbation of Crohn's disease during sunitinib treatment. | 2014 Feb |
1 |
| 79 |
24120473 | Autocrine VEGF signaling promotes proliferation of neoplastic Barrett's epithelial cells through a PLC-dependent pathway. | 2014 Feb |
1 |
| 80 |
24414551 | A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies. | 2014 Mar |
4 |
| 81 |
24475095 | Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma. | 2014 |
2 |
| 82 |
24482243 | Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. | 2014 Jul |
1 |
| 83 |
24510251 | Sunitinib for refractory malignant pheochromocytoma: two case reports. | 2014 Jul |
2 |
| 84 |
24685916 | Metastatic hepatic epithelioid hemangio-endothelioma: long-term response to sunitinib malate. | 2014 |
2 |
| 85 |
25018885 | Guillain-Barré Syndrome following Treatment with Sunitinib Malate. | 2014 |
2 |
| 86 |
25085632 | Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial. | 2014 Aug 1 |
1 |
| 87 |
25309777 | Molecular pathogenesis and targeted therapies in well-differentiated thyroid carcinoma. | 2014 Sep |
2 |
| 88 |
25515134 | Sunitinib-induced severe toxicities in a Japanese patient with the ABCG2 421 AA genotype. | 2014 Dec 16 |
1 |
| 89 |
26168132 | HIF-1 Dimerization Inhibitor Acriflavine Enhances Antitumor Activity of Sunitinib in Breast Cancer Model. | 2014 |
1 |
| 90 |
23454556 | Study of the cellular mechanism of Sunitinib mediated inactivation of activated hepatic stellate cells and its implications in angiogenesis. | 2013 Apr 5 |
2 |
| 91 |
23459719 | Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches. | 2013 Jun 1 |
1 |
| 92 |
23475388 | Expression of vascular endothelial growth factor (VEGF) and its receptors VEGFR1 and VEGFR2 in primary and recurrent WHO grade III meningiomas. | 2013 Sep |
1 |
| 93 |
23511629 | VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib. | 2013 Mar 19 |
1 |
| 94 |
23522954 | Establishment of a novel experimental model of human angiosarcoma and a VEGF-targeting therapeutic experiment. | 2013 May |
1 |
| 95 |
23626551 | Targeting VEGF-VEGFR Pathway by Sunitinib in Peripheral Primitive Neuroectodermal Tumor, Paraganglioma and Epithelioid Hemangioendothelioma: Three Case Reports. | 2013 Jan |
1 |
| 96 |
23659419 | Acute renal failure during the "off" period after sunitinib administration: possible mechanism of vascular endothelial growth factor cascade hyperactivation. | 2013 Nov |
1 |
| 97 |
23767831 | Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: a novel treatment option. | 2013 Sep |
2 |
| 98 |
23811706 | Targeted therapy of kidney cancer: keeping the art around the algorithms. | 2013 Jul |
1 |
| 99 |
23839492 | Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer. | 2013 Aug 6 |
3 |
| 100 |
23878397 | Platelet-derived growth factor/vascular endothelial growth factor receptor inactivation by sunitinib results in Tsc1/Tsc2-dependent inhibition of TORC1. | 2013 Oct |
3 |